DelMar Pharmaceuticals' (NASDAQ: DMPI) is focused on the development of new cancer therapies for patients whose tumors exhibit features making them resistant to or unlikely to respond to current terapies. DelMar's lead drug candidate, VAL-083 is a 'first-in-class' DNA-targeting agent currently undergoing human clinical trials for the treatment of glioblastoma and solid tumors. (BIOTECanada)(LSBC)